An article produced in Nature Genetics provides guidance on the weight that should be given to genetic evidence in predicting drug mechanisms by investigating the current archive. To broadly capture statistically significant common variant genetic associations, the authors used GWASdb10, which combines data from multiple sources. They manually mapped all traits to the most specific Medical Subject Heading (MeSH) terms applicable to compare among all data sources and derived genes involved in rare, mende¬lian traits from Online Mendelian Inheritance in Man (OMIM). The study sought information about drugs across the various stages of development was drawn from the commercial Informa Pharmaprojects database.
After analysing the overlap between drug targets and their indications with genetic associations for similar traits the authors found that (the) “genetic support increased from 2.0% for target-indication pairs that had only progressed as far as phase I clinical trials to 8.2% for approved drugs.” This substantial increase, according to the authors demonstrate that the “odds of successful drug mechanisms with genetic support are many times greater than without.” Thus the authors estimate that “drug mechanisms with genetic support would succeed twice as often as those without it (from phase I to approval).”